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ABSTRACT: This paper examines how pneumococcal type 6B polysaccharide
conjugated to tetanus toxoid (Pn6B-TT) compares to a 23 valent pneumococcal
vaccine (pneumococcal polysaccharide (PPS)-23) with respect to immunogenicity
and serum opsonic activity in patients with chronic obstructive pulmonary disease
(COPD).
Patients with COPD aged 55–75 yrs were vaccinated with Pn6B-TT (n=10) or with
PPS-23 (n=9). Healthy young adults (HA) were vaccinated with Pn6B-TT as controls.
Total antibodies to serotype 6B polysaccharide were measured by radioimmunoassay
and immunoglobulin (Ig)G antibodies by enzyme-linked immunosorbent assay. Opsonic
activity was measured by a phagocytosis assay using human neutrophils as effector
cells.
The patient groups were comparable by age, smoking history, lung function and use
of steroids. COPD patients vaccinated with Pn6B-TT or PPS-23 showed an increase in
IgG antibodies and a nonsignificant increase in opsonic activity. This was similar to the
increase in IgG and opsonic activity seen in HA. There was a significant correlation
between antibody levels and opsonic activity in COPD patients vaccinated both with
Pn6B-TT and PPS-23.
Pneumococcal antibodies have been shown to confer protection from infection.
The results of the present study indicate that protective immunity can be expected in
elderly chronic obstructive pulmonary disease patients vaccinated with conjugate
vaccines.
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Infections due to Streptococcus pneumoniae con-
tinue to be an important cause of morbidity and
mortality among elderly individuals with a variety of
chronic diseases [1–3]. Pneumococci are the most
frequent causes of community-acquired pneumonia,
which has a mortality rate of 5–10%, despite modern
antimicrobial therapy and intensive care [4, 5].
Although the risk to patients with chronic obstructive
pulmonary disease (COPD) has been disputed [6, 7], a
prospective study showed that patients with chronic
pulmonary, renal and cardiac disease comprised the
most significant risk groups for pneumococcal pneu-
monia and its complications [2].
Vaccination with pneumococcal polysaccharide
(PPS) stimulates antibody production [8] and is
protective in healthy adults [9, 10], but immunogeni-
city is low in certain risk groups [11]. Several pros-
pective randomised studies have failed to show
protection against the development of pneumonia [2,
12, 13], but their validity has been in doubt because of
the lack of statistical power [14]. Case-control studies
seem to indicate efficacy in preventing bacteraemia,
which complicates 15–25% of hospitalised pneumonia
cases [10], but have the disadvantage of possible
selection bias. The increasing spread of penicillin-
resistant pneumococci worldwide has added to the
need for a vaccine of undisputed efficacy [15, 16]. To
increase immunogenicity, protein-conjugated PPS
vaccines have been developed [17]. Pneumococcal
conjugate vaccines have been shown to be immuno-
genic [17–20] and highly effective against invasive
disease in children unresponsive to PPS [20].
In the present study, antibody responses and
opsonic activities were compared in the sera of elderly
patients with COPD, vaccinated either with pneumo-
coccal type 6B polysaccharide conjugated to tetanus
toxoid (Pn6B-TT) or with PPS-23. An increased
antibody response of healthy adults to this experi-
mental vaccine compared to PPS was previously
reported [17], but the vaccine had not been tested in
at-risk adults. The antibody responses and opsonic
activity of sera from healthy adults immunised with
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Pn6B-TT were also studied as a control group. The
safety and immunogenicity of Pn6B-TT after repeated
vaccinations has been reported [18, 19].
Materials and methods
Informed consent was obtained from the patients
and healthy adult volunteers and the protocol was
reviewed and approved by the Ethics Committees
of the National University Hospital and Reykjavik
City Hospital in Reykjavik, Iceland (Assurance no.
S-8172-01), the Medical Board of the National Institutes
of Health, Bethesda, MD, USA (protocols OH93-CH-
NO19 and OH93-CH-NO24), and the United States
Food and Drug Administration (FDA) (BB-IND
1977) according to European and USA regulations.
Vaccines and vaccinees
Pn6B-TT was prepared at the Laboratory of
Developmental and Molecular Immunity, National
Institute of Child Health and Human Development,
Bethesda, MD, USA (Lot 55683). Twenty-three valent
PPS vaccine (Imovax) was obtained from Pasteur
Me´rieux, Lyon, France.
Vaccinees were injected with 0.5 mL of Pn6B-TT
containing 12 mg of type 6B polysaccharide and
37.5 mg tetanus toxoid or with 0.5 mL of Imovax
(Pasteur Me´rieux) containing 25 mg of each of the
23 serotypes in the vaccine. Healthy adult volunteers
aged 23–50 yrs (median 28.9 yrs) received one injec-
tion of Pn6B-TT (healthy adults (HA), n=15) or one
dose of Imovax (controls, n=15). Ten elderly indivi-
duals with stable COPD received a single injection of
0.5 mL of Pn6B-TT (group A), and nine received a
single injection of the PPS-23 Imovax (group B). Each
subject had to meet all of the following entry criteria:
1) clinical diagnosis of COPD of any type; 2) aged
55–75 yrs; 3) forced expiratory volume in one second
(FEV1)v1.5 L?s-1, FEV1/forced vital capacityv65%,
andv10% response to bronchodilator; 4) no immuno-
compromising disease or a history of pneumococcal
vaccination or infection with pneumococcus type 6B;
5) received no steroids or equivalent to v15 mg
prednisolone per day. Blood samples were collected
before and 1 month after the vaccination. Sera were
kept in aliquots at -20uC for antibody measurements
and at -70uC for analysis of opsonic activity. Anti-
body responses and opsonic activities were compared
between the COPD patients and the healthy adults.
Antibodies
Immunoglobulin (Ig)G anti-Pn6B was measured
by enzyme-linked immunosorbent assay (ELISA),
according to the protocol recommended by the
pneumococcal workshop at the Centers for Disease
Control and Prevention, Atlanta, GA, USA, October
1994, with minor modifications [18]. In brief, ELISA
plates (Costar, Cambridge, MA, USA) were coated
with 10 mg?mL-1 Pn6B polysaccharide (American
Type Culture Collection, Rockville, MD, USA)
for 5 h at 37uC. Standard and test sera were diluted
1:25 and adsorbed with 50 mg?mL-1 of cell wall
polysaccharide (CWPS) (Statens Seruminstitute,
Copenhagen, Denmark) for 30 min at room tempera-
ture, prior to incubation in four two-fold dilutions
for 2 h in the Pn6B-coated plates. Pn6B-IgG was
detected by incubation with biotin-labelled mono-
clonal antibody HP-6043 (Hybridoma Reagent
Laboratory, Baltimore, MD, USA) at 1:500 dilution,
followed by incubation with alkaline phosphatase-
labelled avidin (DAKO, Glostrup, Denmark) at
1:2,000 dilution for 1 h. The reaction was developed
by p-nitrophenyl phosphate (Sigma, St Louis, MO,
USA) and optical density read at 405 nm in a Titertek
Multiscan Spectrophotometer (Flow Laboratories,
Irvine, UK). IgG anti-Pn6B levels are expressed in
mg?mL-1, calculated from a curve generated by serial
dilutions of an in-house standard prepared from an
adult post 23-valent PPS vaccination pool, calibrated
against reference serum 89SF, provided by C.E.
Frasch, US FDA, Rockville, MD, USA.
Total anti-Pn6B antibodies (Ab) were measured
by radio-immunoassay (RIA) [21] and the results
expressed in ng Ab N?mL-1 (conversion factor for ng
Ab N?mL-1 to Ab concentration is 6.25).
Bacteria
Freeze-dried S. pneumoniae serogroup 6 was recon-
stituted in Todd Hewith broth and subcultured on
sheep blood agar (37uC, 5% CO2). By subtyping with spe-
cific monoclonal antibodies (Statens Seruminstitute),
this strain was found to be of serotype 6A (after
the study had been completed). Colonies were
harvested and suspended in Tryptoset broth (Difco
Laboratories, Detroit, MI, USA) for storage in -70uC.
For radiolabelling, a culture with an initial density of
16104 colony forming units?mL-1 was started in 5 mL
of Rosswell Park Memorial Institute (RPMI) 1640
(GIBCO, Life Technologies GIBCO BRL, Paisley,
UK), supplemented with 10% foetal calf serum
(FCS; GIBCO) and 500 mCi of 3H-labelled-lysine
(Amersham, Amersham, UK), collected in mid-log
phase by centrifugation at 2,2006g for 20 min, and
washed in Hank9s balanced salt solution (HBSS,
GIBCO) containing 5% FCS. The labelled pneumo-
cocci were adjusted to 1.56107 bacteria?mL-1 in HBSS
with 5% FCS and used immediately. The viability
and density was confirmed by plate colony counts
for each experiment.
Phagocytes
Fresh polymorphonuclear leukocytes (PMNLs)
were isolated from the peripheral blood of a healthy
adult volunteer by dextran sedimentation followed by
ficoll (Histopaque, Sigma) gradient centrifugation to
remove mononuclear cells. The final concentration
was adjusted to 1.56106 PMNL?mL-1 HBSS. The
blood donor was FccRIIa-H131 homozygote (kindly
genotyped by C.L. Anderson and J.M. Osborne, Ohio
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State University College of Medicine, Columbus, OH,
USA), and FccRIII-NA1/NA2 heterozygote (typed
using fluorescence staining with monoclonal anti-
bodies (MAb) CLBgran11 and GRM1 and analysis
by flow cytometry (FACS); the MAbs were a kind gift
from M. de Haas and A.E.G. Kr. von dem Borne,
CLB, Amsterdam, The Netherlands).
Opsonophagocytosis
Sera were assayed as described [22] with minor
modifications, using fresh polymorphonuclear cells
(PMN) and 3H-labelled Pn6B without added comple-
ment [19]. Bacterial and PMN suspensions (150 mL of
each, ratio of y10:1) were mixed with test sera at a
concentration predetermined to be in the sensitivity
range of the assay [8, 22]. The total volume of 0.5 mL
was incubated with rotation (250 rev?min-1) for
30 min at 37uC. Controls for nonspecific binding
(NSC; with all reactants except heat-inactivated
FCS instead of human serum) and total bacteria
input (TB; with all reactants) were included in each
assay. The reaction was stopped by adding 2 mL of
phosphate buffered salinez0.02% NaN3. The PMNs
and the cell-associated bacteria (CAB) were pelleted
by centrifugation at 1606g, except that TB was
centrifuged at 2,2006g. After washing, cell pellets
were resuspended in 0.5 mL of 1.25% deoxycholate
and transferred to 4.5 mL of scintillation liquid
(Hionic-fluor, Packard Bioscience, Meriden, CT,
USA). The radioactivity (range 500–10,000 counts
per min (cpm)) was measured in a liquid scintillation
counter (Packard Bioscience) and per cent uptake of
3H-labelled bacteria was calculated as:
(cpm CAB  cpm NSC)
(cpm TB  cpm NSC) |100% ð1Þ
Statistical analysis
A paired t-test was used on log-transformed values
for comparison within groups and nonparametric
signed-rank test when normal distribution was not
obtained. For comparison between groups, a t-test
was used except when normality failed or variance was
unequal, then the Mann-Whitney rank-sum test was
used. Pearson correlation was used to evaluate the
relationship between opsonic activity and antibody
concentration. A p-value of v0.05 was considered
significant.
Results
Subjects
The two groups of patients with COPD were
comparable with respect to age, smoking history and
degree of functional impairment (table 1). Of the
patients who received Pn6B-TT or PPS-23, the mean
ages were 69 and 68 yrs, the mean % predicted values
for FEV1 were 29% and 37% (p=0.09), and the
duration of smoking was 46 yrs and 35 yrs, respec-
tively (p=0.80). Five of 10 patients who received Pn6B-
TT were being treated with steroids compared to three
of 10 patients who received PPS-23.
Antibodies
Before vaccination, the geometric mean (GM) total
Pn6B antibody level in the sera of the two patient
groups were 466 and 398 ng Ab N?mL-1, respectively,
and above the level considered to be protective [21].
Table 2 shows the GM antibody levels of each group
before and after vaccination by the two antibody
measuring methods. As a whole, the groups res-
ponded with a highly significant rise in antibody levels
to both vaccines. There was no difference in the
postvaccination levels of IgG or total antibody in the
COPD patients receiving Pn6B-TT or the PPS-23.
Two patients in each group had very low prevaccina-
tion levels of antibody and no rise after vaccination,
whereas one patient in group A and two in group B
had very high prevaccination levels and no further
increase after vaccination. This was found both for
total and IgG antibodies and demonstrates the
individual variability in natural immunity and the
response to vaccination. This lack of response did
Table 1. – Characteristics of vaccinated patients with
chronic obstructive pulmonary disease
Vaccine group Age
mean
% pred
FEV1
Smoking
yrs
Steroids
n
A: Pn6B-TT# 69 29 46 5/10
B: PPS-23} 68 37 35 3/9
p-value 0.67 0.09 0.80 0.46
FEV1: forced expiratory volume in one second; Pn6B-TT:
pneumococcal type 6B polysaccharide conjugated to tetanus
toxoid; PPS-23: pneumococcal polysaccharide 23. #: n=10;
}:
n=9. A p-value ofv0.05 was considered significant.
Table 2. – Antibodies to serotype 6B pneumococcal
polysaccharide (anti-Pn6B) before and after vaccination
of chronic obstructive pulmonary disease (COPD) and
healthy adults (HA)
Group
A B C
Vaccine Pn6B-TT PPS-23 Pn6B-TT
IgG mg?mL-1
Pre 2.39 2.99 2.45
Post 4.69 5.73 7.32
p-value 0.0138 0.0231 0.0017
Total ng Ab N?ml-1
Pre 466 398 340
Post 1323 1159 1373
p-value 0.0127 0.0143 0.0001
Pn6B-TT: pneumococcal type 6B polysaccharide conjugated
to tetanus toxoid; PPS-23: pneumococcal polysaccharide 23;
IgG: immunoglobulin G; Ab: antibody. A: COPD, n=10; B:
COPD, n=9; C: healthy adults, n=15. A p-value ofv0.05 was
considered significant.
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not relate to steroid intake. All other individuals
had a substantial increase in antibody levels after
vaccination. Healthy adult volunteers injected with
Pn6B-TT responded with a significant rise in total and
IgG antibodies (table 2). The HA group had a similar
GM prevaccination level as both COPD groups, but
slightly higher postvaccination levels; 7.32 versus 4.69
and 5.73 mg IgG?mL-1 and 1,373 versus 1,323 and
1,159 ng Ab N?mL-1, respectively. The differences
were not statistically significant.
Unlike the authors9 previous experience with a
Pn6A [17], the response to the polysaccharide and
the Pn6B-TT conjugate was comparable to that seen
with PPS-23 in the present study. This prompted a
reanalysis of this vaccine lot. No disintegration of the
conjugate was detected, but the concentration of the
conjugate was found to be only half of the original
concentration (the rest was found attached to the
vials). This could be related to the lesser antibody
response.
Opsonisation
The sensitivity range of the opsonisation assay is
narrow and opsonisation reaches a plateau of y60%
uptake at high serum antibody concentration. The 5%
serum concentration was in the sensitivity range of the
assay and was chosen for measurements of opsonic
activity of adult sera.
In agreement with the rise in anti-6B antibodies,
many of the COPD patients vaccinated with PPS-23
or with Pn6B-TT showed a vaccine-induced increase
in opsonic activity (fig. 1), although not significant for
either group. In the healthy adult volunteers vacci-
nated with Pn6B-TT, a highly significant increase in
opsonic activity was observed. The GM postvaccina-
tion opsonisation activities were similar in both
COPD groups (p=0.811), but there was a marked
individual variation in all groups.
When the postvaccination antibody levels were com-
pared to the opsonising activity of sera as measured in
the phagocytosis assay, an excellent correlation was
found. Figure 2 shows the relationship between
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Fig. 1. – Opsonic activity measured as % uptake of radiolabelled pneumococci by polymorphonuclear cells, mediated by pre- and
postvaccination sera from a) chronic obstructive pulmonary disease (COPD) patients vaccinated with pneumococcal type 6B
polysaccharide conjugated to tetanus toxoid (Pn6B-TT) (p=0.066), b) COPD patients vaccinated with pneumococcal polysaccharide-23
(p=0.094), or c) healthy adults vaccinated with Pn6B-TT (p=0.001). A p-value ofv0.05 was considered significant.
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Fig. 2. – Relationship between opsonic activity (% uptake of
pneumococci) and a) 6B immunoglobulin G (IgG) antibody levels
(r=0.702, pv0.001) or b) 6B total antibody levels in postvaccina-
tion sera (r=0.779, pv0.001) from chronic obstructive pulmonary
disease (COPD) patients vaccinated with pneumococcal type 6B
polysaccharide conjugated to tetanus toxoid (Pn6B-TT) (&),
COPD patients vaccinated with pneumococcal polysaccharide-23
(%) or healthy adults vaccinated with Pn6B-TT (+). Ab: anti-
body. A p-value ofv0.05 was considered significant.
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opsonic activity and the postvaccination antibody
levels for anti-Pn6B in ng Ab N?mL-1 as measured by
RIA and in mg IgG?mL-1 measured by the ELISA for
all COPD and HA subjects. The correlation between
opsonic activity and antibody levels was high for total
antibodies using RIA values (r=0.779, pv0.001) and
for IgG antibodies (r=0.702, pv0.001) measured by
ELISA. The relationship between postvaccination
IgG and opsonisation was analysed among COPD
patients according to the vaccine given. There was a
highly significant correlation in the Pn6B-TT group
(r=0.783, p=0.007), and a slightly lesser one in the PPS-
23 group (r=0.749, p=0.020). Similar results were
obtained by RIA, which correlated significantly with
opsonisation both in the Pn6B-TT group (r=0.713,
p=0.021) and in the PPS-23 group (r=0.768, p=0.026).
The antibody measurements, therefore, reflect func-
tional activity.
Discussion
In the present study, the authors compared the
antibody response and opsonic activity of sera from
two groups of patients with COPD, one vaccinated
with Pn6B-TT and the other with PPS-23. Both
groups were found to respond with significant rises
in antibody levels comparable to that seen in a group
of HA vaccinated with Pn6B-TT. The majority of
individuals responded to the vaccinations with a
marked increase in antibody levels; however, in each
group of patients there were individuals who did not
respond, demonstrating the individual variability in
the response to vaccination with these antigens.
The rise in antibody levels measured as IgG or total
antibody was accompanied by a corresponding inc-
rease in opsonic activity of sera indicating the forma-
tion of a functionally active antibody. There was a
similar correlation between postvaccination IgG or
total antibody and opsonic activity for the group
vaccinated with Pn6B-TT or PPS-23. In previous
studies the authors demonstrated that the antibodies
produced in response to vaccination with Pn6B-TT
are primarily IgG1 [19], which is known to activate
complement readily.
In an earlier study of healthy individuals, greater
antibody production had been shown following
vaccination with Pn6B-TT compared with PPS [17].
A booster effect could not be elicited following
repeated injections with the Pn6B-TT conjugate
vaccine [17]. Similar results were obtained by others
in a study of older adults using CRM197 conjugate
where the magnitude of antibody responses to the
conjugate vaccine and PPS-23 were similar, and no
booster effect could be found after re-injection with
PPS-23 following CRM197-conjugate vaccine [23].
However, in a study of patients with Hodgkin9s
disease primed with heptavalent outer membrane
protein conjugate, a strong booster effect following
subsequent vaccination with PPS-23 was seen for five
of the six serotypes tested [24]. These findings suggest
that immune responses to conjugate vaccines in adults
may be dependent on the carrier protein to which the
PPS is conjugated, the vaccination schedule, vaccine
constituents and/or related to host factors.
Pneumococcal serotype-specific opsonic activity of
sera may be a more direct indicator of the protective
potential of an experimental vaccine than serum anti-
bodies alone. Protection from pneumococcal infection
depends primarily on opsonisation of the bacteria by
type-specific serum antibodies and complement. The
present authors have shown for several pneumococcal
serotypes that in adults vaccinated with polysac-
charide vaccine, opsonic activity of sera correlated
best with IgG anti-PPS [8], while antibodies to the
pneumococcal CWPS had little opsonic activity [22].
Human antibody responses to PPS in adults have been
reported to be primarily of the IgG2 subclass [25],
which does not readily activate complement unless at
high concentrations or high epitope density [21, 26,
27]. Furthermore, PPS are T-cell independent anti-
gens of type 2 that do not generate immunological
memory. Antibodies produced following vaccination
of children and healthy adults using experimental PPS
conjugated to proteins are primarily of the IgG1
subclass, which readily activates compliment. Such a
T-cell dependent characteristic and a booster response
have been demonstrated in children and patients with
Hodgkin9s disease using protein-conjugated pneumo-
coccal polysaccharide vaccines [20, 24].
In a recently reported efficacy study in children, a
heptavalent pneumococcal conjugate vaccine was
highly efficacious against invasive disease [20]. These
findings offer hope that similar advances can be
achieved for the large population of adults at risk for
serious pneumococcal infections.
The controversy regarding the efficacy of PPS-23 in
adults at risk has probably reduced the usage of this
vaccine in many parts of the world [3]. Further studies
are needed to test the immunogenicity and efficacy
of pneumococcal conjugate vaccines in adults at
risk. The ability to elicit booster responses after repea-
ted injections also requires further study. Such stu-
dies could provide valuable information on how to
improve immunity against this important pathogen
and to resolve the controversy regarding the utility of
pneumococcal vaccination in the elderly and chroni-
cally ill.
In previous studies of pneumococcal immunity
among patients with COPD, these individuals have
been shown to have higher levels of antibodies than
healthy adults presumably as a result of frequent
antigen exposure [6, 21]. The antibody response to
vaccination with PPS has usually been comparable to
that of healthy controls, but levels have shown a more
rapid decline with time [28, 29]. According to the
present study and previous reports [30], the antibody
response to vaccination does not appear to be
influenced by the prevaccination antibody level or
the age of the recipient.
In the present study, it has been demonstrated that
pneumococcal type 6B polysaccharide conjugated to
tetanus toxoid induced production of functional
antibodies in elderly patients with chronic obstructive
pulmonary disease. The results indicate that protective
immunity can be expected in elderly chronic obstruc-
tive pulmonary disease patients vaccinated with
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protein-conjugated polysaccharide vaccines. Repeated
injections might be beneficial in this age group,
although this remains to be shown. Considering that
serotype 6B is one of the least immunogenic pneumo-
coccal polysaccharides, it is anticipated that the
response to the other serotypes will be better and
conjugate vaccines will prove to be more effective
against pneumococcal disease in adults at risk.
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